Funding Daily Summary
Funding Daily Summary: What Happened on October 21, 2026
Nouscom raises €120 million to advance cancer vaccine
The financing will support NOUS-209. Nouscom plans to present long-term study results in Lynch Syndrome carriers on October 25.
Today in brief
Nouscom raised €120 million in an oversubscribed Series D to advance its lead program, NOUS-209.1 Long-term results from a Phase Ib/II study in Lynch Syndrome carriers are due at ESMO on October 25.1
Nouscom secures €120 million for NOUS-209
M Ventures and Revelation Partners led the round. Angelini Industries, the European Investment Bank and Neva SGR joined as new investors.1 Existing investors also participated.1
Nouscom is studying NOUS-209 as a preventive immunotherapy for people with Lynch Syndrome, an inherited condition that raises cancer risk.1 The company plans to present long-term Phase Ib/II results from the study in Madrid on October 25.1